Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ETC 642

Next Previous
X
Search
Drug Profile

ETC 642

Alternative Names: ESP-24218; ET-642; ETC-642; RLT Peptide

Latest Information Update: 14 Mar 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Clinic
  • Developer Pfizer
  • Class Amino acids; Phospholipids
  • Mechanism of Action Apolipoprotein A-I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 28 Feb 2008 Discontinued - Phase-II for Atherosclerosis in USA (IV)
  • 31 Jul 2007 Phase-II clinical trials in Atherosclerosis in USA (IV)
  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top